title: Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study.
abstract: Few data are available on cognitive and psychiatric effects of topiramate (TPM) monotherapy in migraine. Twenty patients affected by migraine were treated with TPM monotherapy. At the same time, twenty control subjects were selected. A comprehensive neuropsychological and behavioural battery of tests were performed at baseline (T0), at titration (T1) and in maintenance period (T2). Topiramate serum levels were also investigated at T1 and T2. On comparison with the control group, no cognitive and psychiatric differences were detected at baseline. A significant reduction of word fluency score (P < 0.05) was evident after TPM treatment, both at T1 and T2. No patient developed psychiatric adverse events. TPM induced an impairment of verbal fluency and no psychiatric adverse events, demonstrating selective negative cognitive profile in migraine therapy. Slow titration, low doses, lack of previous psychiatric disorders and/or familial history may explain our data.
authors.affiliation: Servizio di Neurofisiopatologia, Centro di Medicina del Sonno, Policlinico Tor Vergata, University of Rome 'Tor Vergata', Rome, Italy, and Fondazione Santa Lucia, Rome, Italy. a_romigi@inwind.it
authors.forename: A
authors.initials: A
authors.lastname: Romigi
authors.forename: A
authors.initials: A
authors.lastname: Cervellino
authors.forename: M G
authors.initials: MG
authors.lastname: Marciani
authors.forename: F
authors.initials: F
authors.lastname: Izzi
authors.forename: R
authors.initials: R
authors.lastname: Massoud
authors.forename: M
authors.initials: M
authors.lastname: Corona
authors.forename: F
authors.initials: F
authors.lastname: Torelli
authors.forename: S
authors.initials: S
authors.lastname: Zannino
authors.forename: E
authors.initials: E
authors.lastname: Uasone
authors.forename: F
authors.initials: F
authors.lastname: Placidi
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects*; D005260:Female; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced*; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D009483:Neuropsychological Tests; D011594:Psychometrics; D000077236:Topiramate; D016896:Treatment Outcome; D014705:Verbal Behavior / Q000187:drug effects*
chemical_list: D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose